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Nociceptin/orphanin FQ (N/OFQ) is a seventeen-amino acid peptide that is the endogenous ligand of a G-protein-coupled
receptor (NOP). Various immune cells express the precursor protein and secrete N/OFQ as well as display binding sites for this
peptide. The functional capacity of NOP receptor was demonstrated in vitro and in vivo studies by the ability of N/OFQ to induce
chemotaxis of immune cells, to regulate the expression of cytokines and other inﬂammatory mediators, and to control cellular
and humoral immunity. In this context, N/OFQ could modulate the outcome of some inﬂammatory diseases, such as sepsis and
autoimmune pathologies by mechanisms not clearly elucidated yet. In fact, human body ﬂuid revealed increased levels of N/OFQ
undersepsis,arthritis,andParkinson’sdiagnose.PreclinicalstudiespointedtotheblockadeofNOPreceptorsignalingassuccessful
in treating these experimental conditions. Further preclinical and clinical studies are required to investigate the potential of NOP
ligands in treating inﬂammatory diseases.
1. N/OFQ andNOP Receptor
The peptide nociceptin/orphanin FQ (N/OFQ) was isolated
fortheﬁrsttimein1995bytwodistinctresearchgroupsfrom
rat [1] and porcine [2] brain extracts. N/OFQ is composed
by seventeen amino acids residues, and this peptide was
nominated nociceptin due to the hyperalgesic eﬀects that it
evokes after supraspinal administration [1]. The other name,
orphanin FQ, was given by the Reinscheid’s group due to
the fact that this peptide displayed aﬃnity to an orphan
receptor—actually, this was one of the ﬁrst well-experienced
cases of reversal pharmacology; while F and Q were used
to discriminate the amino acids phenylalanine from the N-
terminal and glutamine located in the C-terminal position
[2].
N/OFQ is a neuropeptide sharing sequence homology
with classical opioid peptides, but with a distinct pharma-
cologicalproﬁle.N/OFQwasbeingconsideredanopioid-like
peptide,sinceitisstructurallyrelatedtoendogenousopioids,
particularly dynorphin A; however, N/OFQ does not bind
to classical opioid receptors [2]. Additionally, N/OFQ is the
endogenous ligand for the N/OFQ peptide (NOP) receptor
(nominated before as opioid receptor like-1, abbreviated as
ORL-1),whichiscloselyrelatedtotheopioidreceptorfamily,
but does not bind opioid ligands [3]. NOP, similar to the
opioid family, is a receptor coupled to a G-protein. Thus,
the activation of the N/OFQ signaling via NOP receptor can
lead, among other eﬀects, to inhibition of adenylate cyclase,
blockade of Ca2+, and opening of K+ channels (for a review,
see [4]), as described in details in Section 5.
The N/OFQ peptide precursor (ppN/OFQ) and NOP
receptorarewidelyexpressedinthenervoussystemaswellas
in peripheral organs and the immune system. In the central
nervous system, of particular interest is the expression of
NOPreceptorintheforebrain,includingcorticalareas,olfac-
tory regions, the thalamus, and a variety of limbic structures,2 Journal of Amino Acids
such as the hippocampus, the amygdaloid complex, and in
several nuclei of the hypothalamus, that are involved in the
processingofemotionalstimuli.Somebrainstemareas,asthe
periaqueductal gray, on serotoninergic and noradrenergic
nuclei (i.e., raphe complex and locus coeruleus), and several
sensory and motor nuclei also express NOP receptors (for
ar e v i e w ,s e e[ 5]). In contrast to the expression of NOP
receptors, the distribution of the ppN/OFQ mRNA is almost
limited to the limbic areas [6, 7].
In the periphery, NOP receptor has been detected in the
peripheral nervous system and several organs, such as rat
intestineandvansdeferens[8],retina[9],heart[10],porcine
gastrointestinal tract and kidney [11], and several guinea-pig
ganglia. However, one of the principal locations of the NOP
receptorintheperipheryistheimmunesystem.mRNAtran-
scripts for the NOP receptor have been detected in mouse
splenic lymphocytes (CD4+,C D 8 +,C D 4 −, and CD8−)[ 12].
In the human immune system, NOP receptors are also
expressed in lymphocytic B and T-cell lines, monocytic
cell lines, circulating lymphocytes, and monocytes [13, 14].
Taken together, this wide central and peripheral distribution
of NOP expression may explain the broad spectrum of
biological actions of this peptidergic system. In fact, in vivo,
experimental studies have demonstrated that N/OFQ mod-
ulates a variety of biological functions, such as nociception
[1, 2], food intake [15], learning and memory processes
[16], spontaneous locomotor activity [2], rewarding actions
of opioids [17] and ethanol [18], and responses to stress
and anxiety [19]. Peripheral eﬀects, such as hypotension,
bradycardia [20], diuresis [21], inhibition of gastrointestinal
[11]a n da i r w a y[ 22] motility, and/or some reﬂexes such as
coughing [23] and the micturition reﬂex [24] have also been
reported for N/OFQ. Most recently, the eﬀects of N/OFQ-
NOP receptor system in modulating immune functions
have received particular attention, in special its involvement
in sepsis, inﬂammatory, and autoimmune diseases. In this
review, we focus on summarizing the experimental evidence
that suggests an important role played by this peptidergic
system in the modulation of the immune functions, and we
highlight the potential therapeutic eﬀects of NOP ligands in
the treatment of diseases which involve immune responses.
2. The Relationship betweenN/OFQ
andImmuneSystem
Neuropeptides have been described as important source of
immunoregulatory molecules [25–27]. In this line, several
evidence suggests that N/OFQ-NOP pathway may act as a
potent regulatory during immune response.
In1995,Halfordandcolleagues[12]reportedfortheﬁrst
timetheexpressionofNOPreceptorsinmouselymphocytes,
while at the same year, Wick et al. [14] described the
expression of NOP receptor mRNA in human peripheral
blood lymphocytes and lymphocytic cell lines. In agreement,
in 1998, Peluso and colleagues [13] detected the expression
of mRNA NOP receptor in the human normal circulating
lymphocytes and also in monocytes. Still in 1998, Pampusch
et al. [28] demonstrated that NOP receptors are also
expressed in the porcine immune cells and, in 2000, the same
research group reported the expression of NOP receptor and
ppN/OFQ mRNA in porcine lymphoid tissue, such as thy-
mus, lymph nodes, spleen, and freshly isolated splenocytes
[29]. Later, it was demonstrated that high-aﬃnity binding
sites for N/OFQ are distributed in human mononuclear [30]
and polymorphonuclear leukocytes [31, 32]. Additionally,
the incubation of human neutrophils with N/OFQ elicited
intracellular signaling which was mimicked by the NOP syn-
thetic agonist, Ro 64-6198, thus reinforcing that NOP recep-
tors are present and functional in human neutrophils [32].
In2002,fortheﬁrsttime,itwasreportedthattheperiph-
eral blood mononuclear cells transcribe ppN/OFQ [30].
Additionally, it was reported that N-formyl-methionine-
leucine-phenylalanine-(fMLP-) stimulated polymorphonu-
clear neutrophils rapidly secrete N/OFQ by exocytosis,
indicating that at least in neutrophils this neuropeptide is
stored in preformed vesicles rather than de novo synthesized
[32]. Nowadays, it is accepted that numerous immune cells
were found to secrete N/OFQ, thus pointing to these inﬂam-
matory cells as a source of N/OFQ. Importantly, several
inﬂammatory mediators including bacterial products (i.e.,
lipopolysaccharide, LPS) and cytokines could modulate
both the transcription of ppN/OFQ mRNA and its protein
expression [33, 34]. Therefore, N/OFQ seems to act as a
paracrine, autocrine, and/or endocrine immunomodulator,
since activated immune cells led to the induction of NOP
receptor mRNA, and the same activated cells were able to
express N/OFQ.
Based on in vitro and in vivo studies, many biological
actions were reported for N/OFQ and NOP receptor system
in modulating immune functions. In vitro studies have
shown that N/OFQ evokes chemotaxis of polymorphonu-
clear [31]a n dh u m a nm o n o c y t e s[ 35], and when injected
in murine air pouches (an animal model to study leukocyte
inﬁltration in vivo), N/OFQ elicits leukocyte inﬁltration in a
concentration-dependent manner [31].
Further studies aiming to investigate the mechanisms by
which N/OFQ stimulates chemotactic responses suggest that
these eﬀects are mediated by NOP receptors, since the selec-
tive blockade of NOP receptors prevent these actions [35]. It
was found also that N/OFQ-stimulated polymorphonuclear
neutrophils inﬁltration was inhibited by treating mice with a
synthetic analog of the aspirin-triggered lipid mediator 15-
epi-lipoxin A4 [31]. Taken together, these data suggest that
N/OFQ, via activation of NOP receptor signaling, acts as a
potent chemoattractant, possibly due to the involvement of
arachidonic acid products.
Evidence from the literature also suggests that N/OFQ-
NOP receptor system plays a role in regulating chemoat-
tractant responses of leukocytes through chemokine sup-
pression [36]. Chemokines are now known to be involved
in mediating chemotaxis, integrin activation and leukocyte-
endothelial cell interactions, leukocyte degranulation, and
release of inﬂammatory mediators and angiogenesis ([37,
38]; for a review, see [39]). Kaminsky and Rogers
[36] reported that N/OFQ suppresses the production of
CCL2/MCP-1 and CCL5/RANTES chemokine protein in
both primary CD14+ human monocytes and monocyte-likeJournal of Amino Acids 3
cell lines. However, this suppression does not seem to be at
the level of transcription, as N/OFQ treatment did not alter
the mRNA levels for these chemokines in monocytes.
As e r i e so fd a t as u p p o r tam o d u l a t o r ye ﬀect of N/OFQ
under cellular immunity, as summarized below. Peluso and
colleagues [40] demonstrated that in vitro N/OFQ could
decrease the proliferative response of human peripheral
blood mononuclear cells stimulated with phytohemagglu-
tinin. Miller and Fulford [34] have found that both the IL-2
production and T lymphocyte proliferation induced by the
mitogen Con A were inhibited by N/OFQ.
Elegant data described by researchers from McLeod’s
Laboratory have elucidated the mechanism by which N/OFQ
modulates human T-cell response. First, the authors showed
that N/OFQ inhibits the proliferative response of T cells
activated by staphylococcal enterotoxin B (SEB) presented
by Chinese Hamster Ovary (CHO) cells transfected with
human HLA DR4 and CD80 [41], and in a subsequent work,
they showed that the suppressive eﬀect of N/OFQ on the
T-cell proliferation could be blocked by the NOP receptor
antagonist UFP-101, an anti-CD80 antibody, an inactivator
of transforming growth factor-β (TGF-β LAP), L-NAME,
and L-NMMA (both NOS inhibitors). They also have shown
that N/OFQ induces the expression of the immunosuppres-
sive modulator indoleamine 2,3-dioxygenase (IDO) [42].
In view of the factors modulating IDO expression, it was
suggested that N/OFQ decreases T-cell proliferation through
IDO expression by a mechanism involving IFN-γ,T G F - β,
prostaglandin and nitric oxide.
The ability of N/OFQ-NOP receptor system in modulat-
ing humoral immunity was also described in the literature.
Recently, it has been demonstrated that N/OFQ, added in
vitro to murine spleen cells at picomolar concentrations,
caused a signiﬁcant suppression of antibody formation
against sheep red blood cells, which was reversed by NOP
antagonists [43]. In addition, N/OFQ given in vivo by
osmotic pump for 48h suppressed the capacity of spleen
cells cultured ex vivo to produce anti-sheep red blood cell
antibody [43]. These studies showed that N/OFQ directly
inhibits an adaptive immune response, that is, antibody
production, both in vitro and in vivo.
In agreement with the evidence for an immunosup-
pressive eﬀe c te v o k e db yN / O F Q ,D ua n dc o l l e a g u e s[ 44]
have shown that in normal rats the intracerebroventricular
administration of N/OFQ, at nmol doses, reduced the NK
cell activity. However, in rats under surgical trauma, N/OFQ
antagonised the immune function depression, and this
anti-immunosuppression evoked by N/OFQ was completely
reversed by the pretreatment with the antisense oligonu-
cleotide to NOP receptor mRNA [44]. Taken together, a
growing body of evidence suggests a complex role for
N/OFQ in modulating, by inhibiting or activating, immune
functions depending on the nature of the stimuli.
3. The Involvement of Inﬂammatory Mediators
inN/OFQ-Evoked Immune Actions
It is well established that regulation of immune and inﬂam-
matoryresponses dependson cytokinessignaling. Therefore,
it is expected that N/OFQ evokes immune responses as a
result of the modulation of cytokine activity or expression.
However,itispossiblethatthealteredexpressionofcytokines
is due to the NOP receptor signaling-induced production of
regulatory mediators which, in turn, lead to altered levels of
cytokines (for a review, see [39]).
There is no consensus regarding the role of N/OFQ on
inﬂammatory and immune responses. In fact, Goldfarb and
colleagues [45] demonstrated that in C57BL/6J mice the
intraperitoneal injection of N/OFQ (55nmol/kg) 30min
before challenge with Staphylococcal enterotoxin A (SEA,
5μg) caused a signiﬁcant increase in levels of spleen TNF-α
and IFN-γ mRNA, without causing any signiﬁcant eﬀects
on IL-1β and IL-2 mRNA levels. Moreover, mice lacking
the N/OFQ precursor gene showed diminished TNF-α and
IFN-γ transcripts in the spleen in response to SEA challenge,
suggesting that N/OFQ system can exacerbate the immune
function.
By contrast, following the induction of trauma in
rats, Zhao and colleagues [46] found typical robust
increases in both TNF-α and IL-1β transcripts in peritoneal
macrophages, but when N/OFQ was intracerebroventricu-
larly administered, both TNF-α and IL-1β expression was
attenuated in these cells. Additionally, N/OFQ immunore-
active cells and mRNA for NOP receptor were signiﬁcantly
reduced after trauma in cerebral cortex, hippocampus,
and hypothalamus of rats [46]. Still under traumatic
stress, high levels of IL-1β transcript in hippocampus were
antagonised by icv administration of N/OFQ, and these
eﬀects were reversed by the treatment with an NOP receptor
antagonist [47], thus suggesting that the eﬀects of N/OFQ
in the cytokines expression could depend on the tissues,
pretreatment time, dose and via of N/OFQ administration,
and nature of stimuli [39]. Obviously, further studies at
this point should be performed in order to give additional
information about the role played by the N/OFQ-NOP
receptor system in the modulating cytokines expression.
It is worthy of mentioning that the inﬂammatory process
is a necessary step for induction of protective immunity and
to contain the infections, but can also lead to dangerous
eﬀects, if uncontrolled. Hence, an imbalance between proin-
ﬂammatory and anti-inﬂammatory mediators, between
Th1/Th17 eﬀector cells and T regulatory cells may result
in hyperinﬂammatory or autoimmune diseases. Considering
the bidirectional relationship between the N/OFQ-NOP
and the immune system, it is possible that NOP receptor
signaling modulates the outcome of some inﬂammatory
diseases including sepsis, autoimmunity, and possibly the
transplantation rejection, a condition not investigated yet.
4. N/OFQ-NOP Receptor Systemand
Inﬂammatory andAutoimmune Diseases
Thecomplexsyndromeofsepsisischaracterizedbyimpaired
recruitment of neutrophils, inability of the immune system
to limit bacterial spread during an ongoing infection and
systemic inﬂammation associated with deleterious accumu-
lation of neutrophils in vital organs, especially the lung that4 Journal of Amino Acids
culminates in multiple organ failure [48–50]. The systemic
inﬂammatory response syndrome (SIRS), hallmark sign of
sepsis, is characterized by a systemic inﬂammatory response
with massive release of proinﬂammatory cytokines such
as TNF-α,I L - 1 β, chemokines, nitric oxide, leukotrienes,
reactive oxygen species [51, 52]. This response is counter-
regulatory by a compensatory anti-inﬂammatory response
syndrome (CARS) through the secretion of inhibitory
molecules such as IL-10 and TGF-β.I th a sb e e ns u g g e s t e d
that in septic patients a delicate balance between the pro and
anti-inﬂammatory mediators are decisive to the outcome of
disease [53], since the proinﬂammatory phase is necessary
for both the recruitment of neutrophils and induction of
microbicidal activity but also responsible for the failure of
neutrophils migration to the infectious focus. In addition, it
may be related to subsequent immunosuppression [49, 54].
Using the caecal ligation and puncture (CLP) model of
sepsis, our group have demonstrated that the administration
of the NOP receptor antagonist UFP-101, immediately after
surgery, promoted a signiﬁcantly reduction on mortality rate
of septic rats compared with CLP-untreated rats [55]. In this
study, we observed that the protective dose of NOP antago-
nist was able to prevent the massive inﬂux of inﬂammatory
cells into both the lung and bacterial dissemination. These
protective eﬀects were associated with signiﬁcant decrease in
p l a s m a t i cl e v e l so fT N F - α,I L - 1 β, and CCL2 [55]. It should
be mentioned that this beneﬁcial eﬀect of UFP-101 was
evident after a single drug injection after induction of CLP,
suggesting that the N/OFQ-NOP system plays an important
role in modulating the early phases of the septic process.
The molecular mechanisms by which the NOP receptor
antagonist, UFP-101 have protected septic rats are under
investigation by our group. In our study, we did not evaluate
the role of nitric oxide and other regulatory molecules such
as programmed death-1 (PD-1)/PD-1 ligands, TGF-β,a n d
CLTA-4 (Cytotoxic T-lymphocyte antigen 4). Although we
have detected a decreased number of bacteria in the blood,
it was not investigated whether NOP antagonist modulates
directly or indirectly the bactericidal activity of neutrophils.
Additional data have supported the idea that high levels
of N/OFQ in septic patients may contribute to its pathogen-
esis. Despite the small size of the sample, it was found that
septic patients who died within 30 days (n = 4) displayed
higher N/OFQ plasmatic levels compared with survivors (n
= 17) [56]. However, when evaluating the role of N/OFQ-
NOP receptor system in a complex event such as sepsis, we
should be aware of the broad range of eﬀects evoked by NOP
receptor signaling, that contribute to the septic condition,
suchasimpairmentofcardiovascularperformanceandtissue
perfusion, beside the immune responses herein discussed
(for a review see [57]). Very recently, Stamer and colleagues
[58] have shown that peripheral blood cells from patients
with sepsis had higher N/OFQ and lower ppN/OFQ mRNA
expression than healthy controls. Again, these observations
suggest the involvement of the NOP-N/OFQ system in
inﬂammation and impaired immune function in sepsis.
Corroborative data showing the involvement of N/OFQ-
NOP system in the physiopathology of other immune
disturbances have been described. In this regard, Fiset and
colleagues [32] found high levels of N/OFQ in the synovial
ﬂuid but not in the plasma of patients with arthritis. In
view of the presence of N/OFQ and polymorphonuclear cells
accumulationintheinﬂammatorysynovialcavityofarthritic
patients, further studies are imperative to investigate the
involvementofN/OFQ-NOPreceptoratthebeginningofthe
inﬂammatory process.
Using a mouse model of bowel disease induced by the
injection of dextran sulfate sodium, Kato and colleagues
[59] demonstrated that both the inﬂammatory response and
severity of disease were associated with the upregulation
of N/OFQ expression. Furthermore, NOP knockout mice
did not develop colitis, thus indicating the participation of
N/OFQindisease[59].Regardingthehistopathologicalﬁnd-
ings,theauthorsfoundthatthenumberofTlymphocytes(T
CD4+ and T CD8+), B lymphocytes, macrophages, and neu-
trophils present in the colonic mucosa of dextran sulphate
sodium-treated NOP-deﬁcient mice was signiﬁcantly lower
than the number of those found in wild-type animals.
Concerning Parkinson’s disease, the second most com-
mon age-associated progressive neurodegenerative disorder,
the inﬂammation, oxidative stress, and microglia-mediated
neurotoxicity of dopaminergic neurons in the substantia
nigra are considered the hallmark of disease [60–63]. Some
ﬁndings for neuroinﬂammatory mechanisms leading to the
immunopathology of Parkinson’s disease include microgial
activation, secretion of TNF-α,I L - 1 β, IL-2, IL-6, and CCL5,
antibody against diﬀerent components of dopaminergic
neurons, expression of inducible nitric oxide synthase,
astrogliosis, shift to Th1 phenotype, increased number of
activated T cells, and other inﬂammatory markers [60–62,
64–69]. Several preclinical studies reported by Professor’s
Morari’s group have suggested the participation of N/OFQ
in the physiopathology of Parkinson’s disease [70–74]. Inter-
estingly, an enhancement of N/OFQ expression and release
in 6-hidroxydopamine hemi-lesioned rats was detected in
the lesioned substantia nigra compared with the unlesioned,
indicating that parkinsonism may be associated with over-
activation of NOP receptor signaling [71]. Furthermore, the
pharmacological blockade of NOP receptor signaling atten-
uates parkinsonian-like behavior in 6-hydroxydopamine
hemi-lesioned, haloperidol, and reserpine-treated rodents,
whereas deletion of the NOP receptor gene conferred mice
protection from these symptoms [71, 74, 75]. Corroborating
to the view that N/OFQ-NOP receptor system plays an
important role in Parkinson’s disease, very recently, Marti
and colleagues [76] found increased levels of N/OFQ in the




The OFQ/N system modulates many functions in a variety
of immune cells including monocytes, macrophages, neu-
trophils, mast cells, and lymphocytes by a mechanism not
clearly elucidated yet. Table 1 summarizes some of these
functions, the participation of N/OFQ in the neuroimmuneJournal of Amino Acids 5
Table 1: Mechanisms underlying some immunoregulatory activities triggered by NOP receptor activation.
Biological eﬀects related to N/OFQ or its
interaction in the neuroimmune axis Mechanisms Animal conditions or cell type Ref
Bacterial products (LPS) and
inﬂammatory cytokines (IL-1β and
TNF-α) increase the expression of
N/OFQ in astrocytes
Dependent on ERK, p38 MAPK, and
NF-κB activation Primary rat astrocytes culture [33]
LPS induce N/OFQ expression in dorsal
root ganglion (DRG) neurons
The complex TLR-4-MD-1 seems to be a
functional receptor of neurons for LPS DRG neurons obtained from mice [77]
N/OFQ induces vasodilatation and
hyperemia in acutely inﬂamed rat knees
Dependent of mast cells, and circulating
leukocytes, which produces
proinﬂammatory factors that stimulate
capsaicin-sensitive nerves leading to




Increased vascular permeability in rat
skin by local application of nociceptin Histamine released from mast cells Wistar rats, peritoneal mast cells
isolated
[79]
N/OFQ i.v. injection induces
hypotension, vasodilatation, vascular
permeability, leukocytes rolling, and
adhesion
Vasodilation and inﬂammation
dependent, of histamine released by mast
cells
Wistar rats [80]
N/OFQ elicits in mice itch and
leukotriene B4 production Not clear ICR mice, keratinocytes from mice [81]
N/OFQ induces chemotaxis of
neutrophils in vitro and leukocytes
recruitment in vivo
The chemotaxis were Ca2+ independent,
and leukocytes inﬁltration into air
pouches cavities were inhibited by
15-Epi-Lipoxin A4 treatment
Human PMN-isolated and murine
air pouches model
[31]
Human neutrophils secrete preformed
N/OFQ upon degranulation induced by
microbial-derived N-formylated protein
N/OFQ prevents cAMP elevation in
fMLP-stimulated PMNs acting as an
activating signal
Human neutrophils [32]
NOP-deﬁcient mice developed attenuated
colitis when orally treated with dextran
sulfate sodium
Decreased expression of MadCAM-1 and
signiﬁcant reduction in the number of
lymphocytes, macrophages and
neutrophils in colonic mucosa
NOP deﬁcient and wild-type
C57BL6 mice
[59]
Pharmacological blockade of NOP
receptor decreases rate mortality and
systemic inﬂammation in septic rats
Control of bacteria spread (peritoneal
cavity and blood) and decreased lung
inﬁltration and serum levels of TNF-α,
IL-1β, and CCL2
Rats subjected to CLP [55]
N/OFQ decreases SEB-activated T-cell
proliferation
Induction of active IDO expression in T
cells by a mechanism involving IFN-γ,
TGF-β, prostaglandin, and nitric oxide
SEB-activated CD4+ Tc e l l s [42]
Modulation of genes transcription
involved in the neuroimmune axis
functions
N/OFQ induces cell signaling via several
intracellular pathways leading to MAP
kinase activation, PKC activation, NFκB
nuclear translocation, and hence gene
transcriptions
Human neuroblastoma SH-SY5Y
cells, CHO transfected cells
[82–85]
CCL2: chemokine (C-C motif) ligand 2; CGRP: calcitonin gene-related peptide; CLP: cecal ligation and puncture; ERK: extracellular signal-regulated kinase;
fMLP:formyl-methionyl-leucyl-phenylalanin;IDO:indoleamine2,3-dioxygenase;MAdCAM-1:mucosaladdresincelladhesionmolecule-1;MAPK:mitogen-
activated protein kinase; MD-1: myeloid diﬀerentiation protein-1; NFκB: nuclear factor Kappa B; PMN: polymorphonuclear neutrophil; SP: substance P;
TLR4: toll-like receptor 4; VIP: vasoactive intestinal peptide.
axis, and the mechanisms underlying some immunoregula-
tory activities triggered by NOP receptor activation.
NOP receptor together with the classical opioids (μ, κ, δ)
receptorsbelongstotheG-protein-coupledreceptor(GPCR)
family, which plays a vital role in the transduction of signals
regulating several eﬀectors. Regarding to N/OFQ, some
authorshavedescribedthattheNOPactivationbyitsnatural
ligand or agonists induces the activation of K+ conductance
and inhibition of voltage-gated Ca2+ channels and either
augments (via activated α-subunit of Gs class of G-protein)
or decreases (via the activated form of the Gi/Go) cAMP
formationinavarietyofcellsincludingimmunecells[1,2,4,
86–88]. N/OFQ also induces stimulation of phospholipase C
(viaα-subunitofGq),whichleadsto1,4,5-triphosphate(IP3)
and diacylglycerol production and also to Ca2+-dependent
protein kinase C (PKC) activation (for a review, see [83, 89,
90]). It was also demonstrated that in CHO cells the type of
G-protein involved in PKC activation by N/OFQ were a Gi/o6 Journal of Amino Acids
G-protein [91]. Moreover, N/OFQ modulates extracellular
signal-regulated kinase (ERK), p38, c-Jun N-terminal Kinase
(JNK)isoformsofmitogen-activatedproteinkinase(MAPK)
[82, 90, 92, 93], and the transcription of a variety of genes
involved in immune and inﬂammatory responses [83, 94]. It
hadbeensuggestedthatthesignaltransducerandactivatorof
transcription(STAT3)maybeinvolvedinthetransductionof
NOP signaling [90, 95].
Considering the glia-immune cells communication, it
was demonstrated that LPS, IL-1β,a n dT N F - α increase the
levels of N/OFQ mRNA and immunoreactivity in rat astro-
cytes in culture by a mechanism dependent of the activation
of ERK 1/2, p38 MAP kinases and the transcription factor
CREB. It was demonstrated that NFκB pathway appears to
be involved in the induction of N/OFQ transcription by LPS
[33]. N/OFQ has been shown to cause IκB kinase (IKK)
phosphorylation and IκB degradation in SH-SY5Y human
neuroblastoma cells [84]. Recently, Donica and colleagues
[85] showed that N/OFQ increases the nuclear translocation,
binding to DNA, and activation of transcription. Hence, the




the Regulation of ImmuneFunctions
As commented above, N/OFQ belongs to the opioid family,
but despite the structural homology between ligands and
receptors, there is no evidence that N/OFQ activates opioid
receptors, neither classical opioid ligands activate NOP
receptor [83]. Importantly, NOP and ppN/OFQ mRNA are
foundexpressedconstitutivelyindistinctcellsoftheimmune
system [1, 45, 96], while kappa opioid receptors are constitu-
tively expressed in lymphocytic cells [97], but this is not the
case of mu and delta opioid receptors [13, 98]. Additionally,
beta-endorphinanddynorphinareexpressedandsecretedby
immunecells,includingTcells,andupregulatedinthesecells
by various stimuli [99–103]. It is wellknown that cytokines,
mediators typically released from immune cells, are potent
regulatorsofmu-opioidreceptorgeneexpression.Infact,mu
receptors are not constitutively expressed in immune cells,
but these receptors are upregulated in T cells and B cells
following pretreatment with interleukin 4 (IL-4) and TNF-
α [104, 105]. Thus, suggesting a putative role of classical
opioids in the regulation of the immune functions.
It is well documented that opioid peptides cause immu-
nosuppressive eﬀects in some assays and stimulatory actions
in others [106–108], however, morphine, which is a pre-
ferred mu receptor agonist, generally has been found to be
immunosuppressive in a variety of assays [109].
The current review has showed that N/OFQ has immu-
nomodulatory actions, by stimulating or inhibiting the
immune system. However, little information is still available
in the literature regarding the relationship between N/OFQ
and classical opioid systems. Anton and colleagues [43]
showed that N/OFQ inhibits antibody formation in a
naloxone-insensitive manner, thus suggesting that N/OFQ
eﬀects, at least in this particular case, are not mediated by
classical opioid receptors [43]. Another recent evidence that
show no interaction between N/OFQ-NOP receptor system
and the classic opioid system is coming from a clinical
study, in which patients suﬀering from cancer who were
taking opioid medication (morphine or equivalents) did not
display any signiﬁcant alterations in NOP and ppN/OFQ
expression compared with those who did not receive opioids
pretreatment [58]. These observations suggest that, despite
the immunosuppressive eﬀects of opioid in addicted patients
[110], the mechanisms by which classical opioids aﬀect
immune functions, especially in the periphery, did not seem
to be related to the N/OFQ-NOP receptor system.
Considering the expression of classical opioids (ligands
and receptors) and N/OFQ-NOP receptor in the central
nervous system, beside the immune cells, a putative neu-
roimmune cross-talk could be suggested. It is accepted that
classical opioids depress the immune function, due to the
activationofthehypothalamic-pituitary-adrenalaxis(HPA),
thus increasing corticoid hormone production [111]. Some
studies have suggested that N/OFQ activates the HPA axis. In
fact, intracerebroventricular injection of N/OFQ in rats led
to increased plasma adrenocorticotropic hormone (ACTH)
concentrations [112] and corticosterone [113] under resting
conditions. N/OFQ administered to rats under mild stress
enhanced the raised ACTH response to stress and prolonged
the higher concentrations of corticosterone, while UFP-101,
an NOP receptor antagonist, signiﬁcantly attenuated plasma
ACTH and corticosterone compared to saline injection in
LPS-treated rats [114]. However, under a more stressful
stimulus, such as restraint, central injection of N/OFQ did
not aﬀect the elevated plasma concentrations of ACTH or
corticosterone [112].
Additionally, Leggett et al. [114] found increased
corticotrophin-releasing factor (CRF) and corticotrophic
pro-opiomelanocortin (POMC; a protein precursor of
ACTH, beta-endorphin, and Met-enkephalin) mRNA into
the parvocellular paraventricular nucleus expression due to
LPS challenge compared to non-LPS treated rats. Addi-
tionally, the intracerebroventricular administration of UFP-
101 in LPS-treated rats was associated with increased
POMC mRNA expression 4h after injection and a clear
trend towards increased parvocellular CRF mRNA. Taken
together, a neuroimmune cross-talk between the N/OFQ-
NOP receptor and classical opioid systems seems to be
occurring and could be involved in the modulation of the
immune responses.
7. Concluding Remark
In conclusion, there is no consensus regarding the role of
N/OFQ-NOP receptor system in modulating inﬂammatory
and immune responses. In fact, some studies have shown
that N/OFQ is able to evoke chemotaxis, inhibit cellular and
humoral immunity, and increase or suppress the expression
of proinﬂammatory cytokines, such as TNF-α and IFN-
γ. Certainly, these immunological eﬀects evoked by this
peptidergic system make the NOP receptor an attractiveJournal of Amino Acids 7
therapeutic target for the treatment of inﬂammatory dis-
eases, such as sepsis, rheumatoid arthritis, colitis, and other
immunological disturbances. Interesting enough, preclinical
ﬁndings from animal models of sepsis, colitis, and Parkinson
pointed to the blockade of NOP receptor signaling as
beneﬁcial to diseases’ outcome. Additional support to the
involvement of N/OFQ in mediating these pathologies was
found in human body ﬂuids from patients suﬀering from
sepsis, arthritis, and Parkinson, which displays increased
N/OFQ levels. Thus, showing the vast range of immune
functions evoked by N/OFQ, an extensive research in basic
and clinical sciences is mandatory to further investigate the
potential therapeutic eﬀects of NOP ligands in the treatment
of inﬂammatory diseases.
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